|
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 23 |
April - June 2007 (Part-I) |
Number 2 |
||
|
|
||||
|
||||
|
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 23 |
April - June 2007 (Part-I) |
Number 2 |
||
|
|
||||
|
||||
Intralesional bleomycin injection: A primary
therapy for peripheral lymphangiomas
Nasir Saleem Saddal1, Ahmad Sharif2, Soofia Ahmad3,
Farhat Mirza4, Nadeem Akhtar5, Anwar-ul-Haq6, Iftikhar Ahmed Jan7
ABSTRACT
Objective: To evaluate the efficacy of intralesional Bleomycin Injection (IBI) as a primary therapy for peripheral lymphangiomas in children.
Methodology: A prospective study was conducted at NICH Karachi from January 2003 to December 2005. Patients with peripheral lymphangiomas were included in the study. Exclusion criteria included previously treated lymphangiomas, infected lesions, intra-thoracic and intra-abdominal lesions. Thirty three patients were included in the study. All were treated with Intralesional Bleomycin Injection (IBI). After aspiration of fluid from the lesion, 0.5 mg/kg of Bleomycin diluted in saline was administered at different sites into the lesion. Depending upon the size of lesion & age of patient, procedure was performed in operating theatre under local or general anesthesia.
Results: Reduction in size was seen in 90% cases (n=29), out of them 30% (n=10) showed near complete disappearance and 63% (n=21) showed good response. Two patients (6%) showed poor response and they underwent surgery. Few patients had minor complications like fever, pain, redness and increase in the size after injection. All these complications were managed conservatively with symptomatic treatment and no patient required hospitalization.
Conclusion: IBI is an effective therapy for lymphangiomas, with results comparable to surgical excision. It has the added advantage of avoiding inadvertent injury to vital structures, scarring and other complications of surgery. We recommend it as a primary therapy for all peripheral lymphangiomas.
KEY WORDS: Bleomycin, Lymphangioma, Sclerosing agents Lymphangiomas management, Intralesional Bleomycin, effective modality.Pak J Med Sci April 2007 Vol. 23 No. 2 220-222
1. Dr. Nasir Saleem Saddal
2. Dr. Ahmad Sharif
3. Dr. Soofia Ahmad
4. Dr. Farhat Mirza
5. Dr. Nadeem Akhtar
6. Dr. Anwar-ul-Haq
7. Dr. Iftikhar Ahmed Jan
1-4: Department of Pediatric Surgery,
NICH, Karachi.
5-7: Department of Pediatric surgery,
The Children’s Hospital PIMS Islamabad.
Correspondences:
Prof. Iftikhar Ahmad Jan,
Professor of Paediatric Surgery,
The Children’s Hospital,
Pakistan Institute of Medical Sciences, G-8/3,
Islamabad- Pakistan.
E-Mail: pedsurg@cyber.net.pk
* Received for publication: August 24, 2006
* Revision Received: September 22, 2006
* Revision Accepted: September 30, 2006
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES
Professional
Medical Publications
Room No. 522, 5th Floor, Panorama Centre
Building No. 2, P.O. Box 8766, Saddar, Karachi - Pakistan.
Phones : 5688791, 5689285 Fax : 5689860
pjms@pjms.com.pk
